monoammonium glycyrrinate
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2018 (NCT03562897)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
- Adnexal Diseases · Phase 2
- Carcinoma · Phase 2
- Colonic Diseases · Phase 2
- Colorectal Neoplasms · Phase 2
- Digestive System Diseases · Phase 2
- Digestive System Neoplasms · Phase 2
- Endocrine Gland Neoplasms · Phase 2
- Endocrine System Diseases · Phase 2
- Female Urogenital Diseases · Phase 2
- Female Urogenital Diseases and Pregnancy Complications · Phase 2
- Gastrointestinal Diseases · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Genital Diseases, Female · Phase 2
- Genital Neoplasms, Female · Phase 2
- Gonadal Disorders · Phase 2
- Intestinal Diseases · Phase 2
- Intestinal Neoplasms · Phase 2
- Neoplasms · Phase 2
- Neoplasms, Glandular and Epithelial · Phase 2
- Ovarian Diseases · Phase 2
- Ovarian Neoplasms · Phase 2
- Rectal Diseases · Phase 2
- Urogenital Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03549273 | Phase 2 | Oct 1, 2018 | Catalysis SL |
| NCT03559543 | Phase 2 | Sep 15, 2018 | Catalysis SL |
| NCT03562897 | Phase 2 | Sep 1, 2018 | Catalysis SL |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Catalysis SL | For profit | 3 | 3 | 1 | 2018 |
1 organizations
Page 1 / 1